CoChat

Tumour-infiltrating inflammatory and immune cells in patients with extrahepatic cholangiocarcinoma

Open access
Kitano, Yuki, Okabe, Hirohisa, Yamashita, Yo-ichi, Nakagawa, Shigeki, Saito, Yoichi, Umezaki, Naoki, Tsukamoto, Masayo, Yamao, Takanobu, Yamamura, Kensuke, Arima, Kota, Kaida, Takayoshi, Miyata, Tatsunori, Mima, Kosuke, Imai, Katsunori, Hashimoto, Daisuke, Komohara, Yoshihiro, Chikamoto, Akira, Ishiko, Takatoshi, Baba, Hideo · 2018 · British Journal of Cancer
Cited by 144

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Inflammation and immune characteristics of the tumour microenvironment have therapeutic significance. The aim of this study was to investigate the clinical impact on disease progression in human extrahepatic cholangiocarcinoma (ECC). A total of 114 consecutive ECC patients with curative resection between 2000 and 2014 were enrolled. Tumour infiltrating CD66b + neutrophils (TANs; tumour associated neutrophils), CD163 + M2 macrophages (TAMs; tumour associated macrophages), CD8 + T cells, and FOXP3 + regulatory T cells (Tregs) were assayed by immunohistochemistry, and their relationships with patient clinicopathological characteristics and prognosis were evaluated. Tumour associated neutrophils were inversely correlated with CD8 + T cells ( P =0.0001) and positively correlated with Tregs ( P =0.001). High TANs ( P =0.01), low CD8 + T cells ( P =0.02), and high Tregs ( P =0.04) were significantly associated with poor overall survival (OS). A high-risk signature, derived from integration of intratumoural inflammatory and immune cells, was significantly associated with poor recurrence-free survival ( P =0.01) and OS ( P =0.0008). A high-risk signature was correlated with postoperative distant metastases. Furthermore, a high-risk signature was related to the resistance to gemcitabine-based chemotherapy used after recurrence. Our data showed that tumour infiltrating inflammatory and immune cells may play a pivotal role in ECC progression and a high-risk signature predicted poor prognosis in ECC patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2017.401

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Metadata

Authors
Kitano, Y., Okabe, H., Yamashita, Y.-I., Nakagawa, S., Saito, Y., Umezaki, N., Tsukamoto, M., Yamao, T., Yamamura, K., Arima, K., Kaida, T., Miyata, T., Mima, K., Imai, K., Hashimoto, D., Komohara, Y., Chikamoto, A., Ishiko, T., & Baba, H.
Venue
British Journal of Cancer
Published
2017-11-09
Volume
118
Issue
2
Pages
171-180
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2767473306
Cited by
144
References
12
FWCI
8.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.